1. Home
  2. PBT vs MLYS Comparison

PBT vs MLYS Comparison

Compare PBT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Permian Basin Royalty Trust

PBT

Permian Basin Royalty Trust

N/A

Current Price

$17.32

Market Cap

920.1M

Sector

Energy

ML Signal

N/A

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$36.92

Market Cap

3.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PBT
MLYS
Founded
1980
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
920.1M
3.1B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
PBT
MLYS
Price
$17.32
$36.92
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$47.33
AVG Volume (30 Days)
74.7K
1.6M
Earning Date
03-13-2026
02-11-2026
Dividend Yield
1.79%
N/A
EPS Growth
N/A
N/A
EPS
0.33
N/A
Revenue
$17,266,423.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$52.31
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.01
$8.24
52 Week High
$20.46
$47.65

Technical Indicators

Market Signals
Indicator
PBT
MLYS
Relative Strength Index (RSI) 43.58 42.18
Support Level $16.25 $36.01
Resistance Level $17.80 $38.23
Average True Range (ATR) 0.69 1.74
MACD -0.05 0.04
Stochastic Oscillator 28.85 31.06

Price Performance

Historical Comparison
PBT
MLYS

About PBT Permian Basin Royalty Trust

Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: